Fibrogen Inc CS (FGEN)

$9.71 +0.69 (7.65%)
Market Cap 39.28M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio 0.00
Volume 34,200
Avg Vol 36,202
Day's Range N/A - N/A
Shares Out 4.05M
Stochastic %K 97%
Beta 0.77
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 8 at 6:49 PM
$FGEN Short note on $KYBN. Pipeline is not exiting/promising enough. Am I missing sth? https://substack.com/profile/160232761-biotech-pharma-investor/note/c-224906627?r=2nece1
2 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 6 at 2:17 PM
$FGEN The article presents compelling preclinical evidence that roxadustat (FG-4592) mitigates renal interstitial fibrosis in CKD models by stabilizing HIF-1α and activating the CX43/ZO-1 pathway, reducing inflammation and improving tubular repair in UUO and cisplatin-induced injury scenarios. This strengthens roxadustat's "multi-tasker" profile, offering promising implications for CKD patients with fibrosis issues. https://link.springer.com/article/10.1186/s40001-026-03942-8
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 5 at 10:46 AM
$FGEN a solid review highlighting the pro-angiogenic effect of roxadustat on tissue regeneration https://www.mdpi.com/2313-7673/11/3/186
1 · Reply
mjtwins16
mjtwins16 Mar. 4 at 7:49 PM
$FGEN Fgen maintains eu patents
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 4 at 2:10 PM
$FGEN This is a very interesting and positive case report — roxadustat once again demonstrates its “multi-tasker” effect beyond anemia: it now shows a pronounced pro-angiogenic effect (stimulation of blood vessel growth via the HIF-1α/VEGF pathway), which is critical for diabetic wound healing — one of the most common comorbidities in CKD/MDS patients. https://link.springer.com/article/10.1186/s13256-026-05926-y
1 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 3 at 4:31 PM
$FGEN lets see the $15+. Enough with the red!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 3 at 9:35 AM
$FGEN https://www.nature.com/articles/s41598-026-42296-3 This preclinical study in aged mice (43–48 weeks old) found that oral roxadustat (FG-4592) for 8 weeks induced pseudohypoxia (HIF upregulation under normoxia) and significantly preserved working memory (Y-maze), increased white blood cell counts, and enlarged hippocampal volume (MRI), while showing trends toward enhanced neuro-regenerative pathways (Tau, JNK, DCX) without increasing neuroinflammation (Iba1, GFAP). It strengthens roxadustat's "multi-tasker" profile by adding brain health and cognitive protection in aging models, potentially relevant for CKD/MDS patients with cognitive issues. However, it remains preclinical (mice only), with limitations such as small sample size for molecular data and no human translation yet — positive momentum but not a near-term FDA catalyst.
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 2 at 3:19 PM
$FGEN Armistice Capital increased its share, now they have 400k shares
2 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 2 at 3:05 PM
$FGEN https://fintel.io/so/us/kynb/armistice-capital-llc
3 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 2 at 12:15 PM
$FGEN two great new articles about Roxadustat: https://www.mdpi.com/1648-9144/62/3/460 and https://www.nature.com/articles/s41574-026-01241-0
1 · Reply
Latest News on FGEN
No data available.
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 8 at 6:49 PM
$FGEN Short note on $KYBN. Pipeline is not exiting/promising enough. Am I missing sth? https://substack.com/profile/160232761-biotech-pharma-investor/note/c-224906627?r=2nece1
2 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 6 at 2:17 PM
$FGEN The article presents compelling preclinical evidence that roxadustat (FG-4592) mitigates renal interstitial fibrosis in CKD models by stabilizing HIF-1α and activating the CX43/ZO-1 pathway, reducing inflammation and improving tubular repair in UUO and cisplatin-induced injury scenarios. This strengthens roxadustat's "multi-tasker" profile, offering promising implications for CKD patients with fibrosis issues. https://link.springer.com/article/10.1186/s40001-026-03942-8
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 5 at 10:46 AM
$FGEN a solid review highlighting the pro-angiogenic effect of roxadustat on tissue regeneration https://www.mdpi.com/2313-7673/11/3/186
1 · Reply
mjtwins16
mjtwins16 Mar. 4 at 7:49 PM
$FGEN Fgen maintains eu patents
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 4 at 2:10 PM
$FGEN This is a very interesting and positive case report — roxadustat once again demonstrates its “multi-tasker” effect beyond anemia: it now shows a pronounced pro-angiogenic effect (stimulation of blood vessel growth via the HIF-1α/VEGF pathway), which is critical for diabetic wound healing — one of the most common comorbidities in CKD/MDS patients. https://link.springer.com/article/10.1186/s13256-026-05926-y
1 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 3 at 4:31 PM
$FGEN lets see the $15+. Enough with the red!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 3 at 9:35 AM
$FGEN https://www.nature.com/articles/s41598-026-42296-3 This preclinical study in aged mice (43–48 weeks old) found that oral roxadustat (FG-4592) for 8 weeks induced pseudohypoxia (HIF upregulation under normoxia) and significantly preserved working memory (Y-maze), increased white blood cell counts, and enlarged hippocampal volume (MRI), while showing trends toward enhanced neuro-regenerative pathways (Tau, JNK, DCX) without increasing neuroinflammation (Iba1, GFAP). It strengthens roxadustat's "multi-tasker" profile by adding brain health and cognitive protection in aging models, potentially relevant for CKD/MDS patients with cognitive issues. However, it remains preclinical (mice only), with limitations such as small sample size for molecular data and no human translation yet — positive momentum but not a near-term FDA catalyst.
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 2 at 3:19 PM
$FGEN Armistice Capital increased its share, now they have 400k shares
2 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 2 at 3:05 PM
$FGEN https://fintel.io/so/us/kynb/armistice-capital-llc
3 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 2 at 12:15 PM
$FGEN two great new articles about Roxadustat: https://www.mdpi.com/1648-9144/62/3/460 and https://www.nature.com/articles/s41574-026-01241-0
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 27 at 4:07 PM
$FGEN We are waiting for news on Roksadustat. Updated the news file https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
1 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 26 at 3:36 PM
$FGEN Beautiful day + My luck+KynB/FGEN= bloodbath
1 · Reply
OnlyTheBestIdeas
OnlyTheBestIdeas Feb. 26 at 8:22 AM
$FGEN I think the most important part of the ASCO GU results was this: "Additionally, higher tumor uptake of FG-3180 demonstrated a trend towards higher probability of PSA50 response (p=0.053), highlighting the potential of FG-3180 as a biomarker for patient selection". Based on the results so far and according to MOA this is most probably going to be the subgroup (maybe around 40% of total) of patients that are going to have the biggest benefit. And fortunately this is exactly what they are testing in ongoing phase 2. I was a little bit disappointed that they didn't say more aabout this but small N made that difficult. On the bright side they still got p=0.053 which I didn't expect. Market cap around 25% of cash and runway until 2028 so I think there's nice runway to get those phase 2 results. Or maybe they should just stop everything and give the cash to investors and get us quick 200%. To be honest I'm not entirely sure which one I would choose.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Feb. 24 at 11:12 PM
$FGEN 10.1 months in the one-prior-ARPI subgroup = very interesting, and begins to look competitive with strong options on an indirect basis, but still too early to treat as equivalent/superior because the data are non-randomized and subgroup-based
2 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 24 at 12:40 AM
$FGEN what a let down. Dmmmmmmm
0 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 23 at 10:18 PM
$FGEN https://www.globenewswire.com/news-release/2026/02/23/3243105/33525/en/Kyntra-Bio-Announces-Positive-Data-from-the-Investigator-Sponsored-Phase-1b-2-Study-of-FG-3246-in-Combination-with-Enzalutamide-in-Patients-with-Metastatic-Castration-Resistant-Pro.html
1 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 23 at 6:55 PM
$FGEN per chat GPT, lol: So in plain terms: Weak/underwhelming reaction: $8.50 ish Neutral/OK reaction: $9.50–$10.00 ish Good reaction (but not shockingly great): $10.50–$11.00 ish If the data is truly exceptional, it could go above that — but that’s not the most likely outcome based on typical biotech after-hours moves.
0 · Reply
Waikiki2010
Waikiki2010 Feb. 23 at 2:32 PM
$FGEN It is going to be an interesting day as ASCO report on fg-3246 will be revealed after hours today, good luck to all fellow SH's.
2 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 22 at 6:08 PM
$FGEN let's have a green week and push this to $12.50+
0 · Reply
topstockalerts
topstockalerts Feb. 20 at 5:19 PM
$FGEN Holding firm at these levels. Buyers keep stepping in on dips. This shows real demand.
0 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 20 at 4:57 PM
$FGEN lets go!!!!!
0 · Reply
mjtwins16
mjtwins16 Feb. 19 at 6:35 PM
$FGEN the reason the corrupt fda rejected roxa was thrombosis. Come to find out it actually reduces it https://www.sciencedirect.com/science/article/abs/pii/S0006295226001395
3 · Reply